Page last updated: 2024-08-24

tenofovir and Weight Gain

tenofovir has been researched along with Weight Gain in 37 studies

Research

Studies (37)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (2.70)	29.6817
2010's	4 (10.81)	24.3611
2020's	32 (86.49)	2.80

Authors

Authors	Studies
Darcis, G; Fombellida, K; Frippiat, F; Lecomte, M; Léonard, P; Maes, N; Meuris, C; Moutschen, M; Paquot, N; Plum, PE; Sauvage, AS; Uurlings, F; Vaira, D	1
Bon, I; Borderi, M; Calza, L; Colangeli, V; Lazzarotto, T; Miani, T; Nuti, B; Viale, P	1
Diggins, CE; Lo, J; Russo, SC	1
Ake, JA; Bahemana, E; Chang, D; Crowell, TA; Dear, NF; Esber, AL; Iroezindu, M; Kibuuka, H; Maswai, J; Owuoth, J; Polyak, CS; Singoei, V	1
Cerankowski, J; Keith, SW; Schafer, JJ; Shimada, A; Walshe, C; Zimmerman, M	1
Aho, I; Kauppinen, KJ; Sutinen, J	1
Brunet, L; Fusco, GP; Fusco, JS; Hsu, RK; Lamori, JC; Mounzer, K	1
Abgrall, S; Allavena, C; Bernard, L; Bregigeon, S; Caby, F; Capeau, J; Costagliola, D; de Truchis, P; Duvivier, C; Enel, P; Grabar, S; Katlama, C; Khuong, MA; Launay, O; Matheron, S; Melica, G; Melliez, H; Meynard, JL; Pavie, J; Piroth, L; Potard, V; Slama, L; Tattevin, P	1
Adede, RO; Ayieko, J; Balzer, LB; Garraza, LG; Havlir, DV; Hickey, MD; Ogachi, SM; Ojwando, H; Orori, G; Petersen, ML; Wafula, E	1
Galindo, MJ; González, CS; Lillo, IS; Rodríguez, AP	1
Allavena, C; Arvieux, C; Becker, A; Cabié, A; Chéret, A; Delpierre, C; Duvivier, C; Hocqueloux, L; Joly, V; Menard, A	1
Hachey, D; Shiluama, R; Singu, BS; van Woerden, I	1
Boyd, A; Reiss, P; Van der Valk, M; Verburgh, ML; Wit, FWNM	1
Amano, K; Bingo, M; Chikasawa, Y; Hagiwara, T; Ichiki, A; Kinai, E; Muramatsu, T; Sekiya, R; Yotsumoto, M	1
Brainard, DM; Brown, TT; Carter, CC; Das, M; Erlandson, KM; Esser, S; Koethe, JR; Lake, JE; Mccomsey, GA; Melbourne, K; Orkin, C; Post, FA; Rockstroh, JK; Sax, PE; Stellbrink, HJ; Waters, L; Wei, X; Zhong, L	1
Chuang, YC; Hung, CC; Kuo, PH; Liu, WC; Sun, HY; Wu, PY	1
Baker, D; Bloch, M; Carr, M; Hoy, JF; Richardson, R; Tong, W	1
Berruti, M; Briano, F; Di Biagio, A; Taramasso, L	1
Barbini, B; Campbell, L; Gilleece, Y; Hamzah, L; Ibrahim, F; Kegg, S; Post, FA; Samarawickrama, A; Vincent, R; Waters, L	1
Burkholder, GA; Collier, AC; Crane, HM; Curtis, L; Delaney, JAC; Eron, JJ; Geng, E; Harding, BN; Henegar, C; Kitahata, MM; Lindström, S; Mathews, WC; Mayer, KH; Moore, RD; Nance, RM; Rodriguez, B; Ruderman, SA; Saag, MS; Van Wyk, J; Vannappagari, V; Whitney, BM; Willig, AL; Wood, BR	1
DeMarais, P; Max, B	1
Hill, A; Shah, S	1
Ait-Khaled, M; Ajana, F; Jones, B; Nascimento, MC; Santos, J; Scholten, S; Smith, DE; Tenorio, AR; van Wyk, J; Wohlfeiler, M; Wright, J; Wynne, B	1
Bradford, Y; Chandiwana, NC; Cindi, Z; Haas, DW; Maartens, G; Sinxadi, P; Sokhela, S; Venter, WDF	1
Bickel, M; Cahn, P; Greaves, W; Johnson, M; Kumar, P; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Wan, H; Xu, ZJ	1
Bernasconi, E; Calmy, A; Cavassini, M; Furrer, H; Günthard, HF; Ledergerber, B; Mugglin, C; Rauch, A; Schmid, P; Stöckle, M; Surial, B; Tarr, PE; Wandeler, G	1
Lake, JE; Trevillyan, J	1
Beyer, AP; Brunet, L; Fusco, GP; Fusco, JS; Hsu, RK; Mallon, PW; Mounzer, KC; Prajapati, G; Wohlfeiler, MB	1
Bowen, AC; Campbell, AJ; Yeoh, DK	1
Bernstein, A; Saber, S; Siegel, M; Sjaarda, A; Sparks, A	1
Darnell, J; Hill, LA; Jain, S; Karris, MY; Qin, H; Reynolds, T; Sun, X	1
Bogner, JR; Gomez, M; Härter, G; Roider, J; Seybold, U	1
Boyer, S; Calmy, A; Delaporte, E; Eymard-Duvernay, S; Kouanfack, C; Leroy, S; Mpoudi-Etame, M; Omgba Bassega, P; Peeters, M	1
Huo, Y; Livingston, EG; Patel, K; Ransom, CE; Scott, GB; Siberry, GK; Watts, HD; Williams, P	1
Clarance, P; Cohen, JT; George, L; Kang, G; Karthik, R; Muliyil, J; Mwamburi, M; Noubary, F; Ooriapdickal, AC; Peter, D; Pulimood, SA; Rupali, P; Sathasivam, R; Thuppal, SV; Varghese, GM; Wanke, CA	1
Allen, PC; Bendele, R; Bennett, DR; Bischofberger, N; Brignolo, LL; Canfield, DR; Castillo, AB; Dearman, TG; Desjardins, J; Hamilton, M; Hirst, LL; Jerome, C; Marthas, ML; Martin, RB; Meyer, DJ; Pedersen, NC; Samii, VF; Spinner, A; Tarara, R; Valverde, C; Van Rompay, KK; Von Morgenland, W	1

Reviews

3 review(s) available for tenofovir and Weight Gain

Article	Year
Metabolic Consequences of Antiretroviral Therapy. Current HIV/AIDS reports, 2022, Volume: 19, Issue:2 Topics: Alanine; Anti-HIV Agents; Female; Glucose; HIV Infections; HIV Integrase Inhibitors; Humans; Tenofovir; Weight Gain	2022
Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy. Current opinion in infectious diseases, 2021, 02-01, Volume: 34, Issue:1 Topics: Alanine; Anti-HIV Agents; Diabetes Mellitus; HIV Infections; HIV Integrase Inhibitors; Humans; Metabolic Syndrome; Tenofovir; Weight Gain	2021
Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV. Current opinion in HIV and AIDS, 2021, 05-01, Volume: 16, Issue:3 Topics: Alanine; Anti-HIV Agents; HIV Infections; HIV Integrase Inhibitors; Humans; Tenofovir; Weight Gain	2021

Trials

4 trial(s) available for tenofovir and Weight Gain

Article	Year
Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG. HIV medicine, 2021, Volume: 22, Issue:2 Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin Resistance; Kidney; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain	2021
Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study. Journal of acquired immune deficiency syndromes (1999), 2021, 06-01, Volume: 87, Issue:2 Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Glucose; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Insulin Resistance; Lamivudine; Lipids; Metabolic Syndrome; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load; Weight Gain	2021
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial. Journal of acquired immune deficiency syndromes (1999), 2021, 06-01, Volume: 87, Issue:2 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Triazoles; Weight Gain; Weight Loss	2021
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. The New England journal of medicine, 2019, 08-29, Volume: 381, Issue:9 Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Obesity; Oxazines; Piperazines; Pregnancy; Pyridones; RNA, Viral; Tenofovir; Viral Load; Weight Gain	2019

Other Studies

30 other study(ies) available for tenofovir and Weight Gain

Article	Year
Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. BMC infectious diseases, 2021, Sep-06, Volume: 21, Issue:1 Topics: Alanine; Anti-HIV Agents; Cardiovascular Diseases; Heart Disease Risk Factors; HIV Infections; Humans; Lipids; Retrospective Studies; Risk Factors; Tenofovir; Weight Gain	2021
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir. AIDS (London, England), 2022, 01-01, Volume: 36, Issue:1 Topics: Alanine; Amides; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain	2022
Weight gain during the dolutegravir transition in the African Cohort Study. Journal of the International AIDS Society, 2022, Volume: 25, Issue:4 Topics: Adult; Anti-HIV Agents; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kenya; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain	2022
Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide. Obesity (Silver Spring, Md.), 2022, Volume: 30, Issue:6 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol; Drug Substitution; Fumarates; HIV Infections; Humans; Retrospective Studies; Sustained Virologic Response; Tenofovir; Weight Gain	2022
Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain. AIDS (London, England), 2022, 08-01, Volume: 36, Issue:10 Topics: Alanine; Anti-HIV Agents; Cholesterol, LDL; Drug Substitution; HIV Infections; Humans; Retrospective Studies; Tenofovir; Weight Gain	2022
Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV. AIDS research and human retroviruses, 2022, Volume: 38, Issue:10 Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Weight Gain	2022
Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort. The Journal of antimicrobial chemotherapy, 2023, 03-02, Volume: 78, Issue:3 Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; HIV Infections; Humans; Obesity; Tenofovir; Weight Gain	2023
Weight Change Following Switch to Dolutegravir for HIV Treatment in Rural Kenya During Country Roll-Out. Journal of acquired immune deficiency syndromes (1999), 2023, 06-01, Volume: 93, Issue:2 Topics: Adult; Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kenya; Male; Oxazines; Prospective Studies; Pyridones; Retrospective Studies; Tenofovir; Weight Gain	2023
Weight gain in HIV-infected patients. AIDS reviews, 2023, Volume: 25, Issue:1 Topics: Adenine; Anti-HIV Agents; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Pyridones; Tenofovir; Weight Gain	2023
Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV-infected people from the French Dat'AIDS cohort: A propensity score-matched analysis. HIV medicine, 2023, Volume: 24, Issue:8 Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Propensity Score; Retrospective Studies; Tenofovir; Weight Gain	2023
Weight gain in Namibians with HIV switching from efavirenz to dolutegravir. International journal of STD & AIDS, 2023, Volume: 34, Issue:12 Topics: Anti-HIV Agents; Benzoxazines; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Weight Gain	2023
No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain. AIDS (London, England), 2023, 10-01, Volume: 37, Issue:12 Topics: Adult; Alanine; Anti-Retroviral Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Virus Integration; Weight Gain	2023
Young age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023, Volume: 29, Issue:2 Topics: Adult; Drug Substitution; East Asian People; HIV Infections; Humans; Retrospective Studies; Tenofovir; Weight Gain	2023
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 09-12, Volume: 71, Issue:6 Topics: Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; Humans; Risk Factors; Tenofovir; Weight Gain	2020
Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020, Volume: 92 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Dyslipidemias; Emtricitabine; Female; HIV Seropositivity; Humans; Lipids; Male; Middle Aged; Quinolones; Retrospective Studies; Tenofovir; Weight Gain	2020
Switch from tenofovir disoproxil fumarate to raltegravir is not associated with weight gain over 96 weeks. AIDS (London, England), 2020, 04-01, Volume: 34, Issue:5 Topics: Adult; Anti-HIV Agents; Body Mass Index; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Raltegravir Potassium; Tenofovir; Weight Gain	2020
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. AIDS (London, England), 2020, 05-01, Volume: 34, Issue:6 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Weight Gain	2020
Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era. Journal of acquired immune deficiency syndromes (1999), 2021, 03-01, Volume: 86, Issue:3 Topics: Adult; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain	2021
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight. International journal of STD & AIDS, 2021, Volume: 32, Issue:1 Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Quinolones; Tenofovir; Weight Gain	2021
Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens. Journal of acquired immune deficiency syndromes (1999), 2021, 07-01, Volume: 87, Issue:3 Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Genome-Wide Association Study; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Polymorphism, Genetic; Prodrugs; Pyridones; South Africa; Tenofovir; Weight Gain	2021
Summary for Patients: Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. Annals of internal medicine, 2021, Volume: 174, Issue:6 Topics: Adult; Alanine; Anti-HIV Agents; HIV Infections; Humans; Lipids; Obesity; Tenofovir; Weight Gain	2021
Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study. Annals of internal medicine, 2021, Volume: 174, Issue:6 Topics: Adult; Alanine; Anti-HIV Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; HIV Infections; Humans; Lipids; Male; Middle Aged; Obesity; Sensitivity and Specificity; Tenofovir; Triglycerides; Weight Gain	2021
Weight gain before and after switch from TDF to TAF in a U.S. cohort study. Journal of the International AIDS Society, 2021, Volume: 24, Issue:4 Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Diabetes Mellitus, Type 2; Female; HIV Infections; Humans; Male; Middle Aged; Sustained Virologic Response; Tenofovir; Treatment Outcome; Weight Gain	2021
Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens. The Pediatric infectious disease journal, 2021, 05-01, Volume: 40, Issue:5 Topics: Adolescent; Alanine; Anti-Retroviral Agents; Body Mass Index; Child; Cohort Studies; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Weight Gain	2021
Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy. Infection, 2022, Volume: 50, Issue:2 Topics: Alanine; Anti-HIV Agents; Drug Substitution; HIV Infections; Humans; Integrase Inhibitors; Retrospective Studies; Tenofovir; Weight Gain	2022
Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen. Medicine, 2021, Aug-27, Volume: 100, Issue:34 Topics: Alanine; Anti-HIV Agents; Body Mass Index; Case-Control Studies; Comorbidity; Female; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Weight Gain	2021
A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017. Infection, 2019, Volume: 47, Issue:1 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cohort Studies; Female; Fumarates; Germany; HIV Seropositivity; Hospitals, University; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Weight Gain; Weight Loss	2019
Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. Journal of acquired immune deficiency syndromes (1999), 2013, Dec-01, Volume: 64, Issue:4 Topics: Adenine; Adolescent; Anti-HIV Agents; Child Development; Female; Humans; Infant; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Weight Gain	2013
Toxicity and clinical outcomes in patients with HIV on zidovudine and tenofovir based regimens: a retrospective cohort study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, Volume: 109, Issue:6 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; Humans; India; Male; Middle Aged; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Weight Gain; Zidovudine	2015
Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:5 Topics: Absorptiometry, Photon; Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Area Under Curve; Blood Chemical Analysis; Bone and Bones; Bone Density; Dose-Response Relationship, Drug; Fanconi Syndrome; Female; Glycosuria; Half-Life; Macaca mulatta; Male; Organophosphonates; Organophosphorus Compounds; Phosphorus; Tenofovir; Time Factors; Weight Gain	2004